SciBase Holding AB has a Cash Ratio of 0.48. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.
The historical rank and industry rank for SciBase Holding AB's Cash Ratio or its related term are showing as below:
OSTO:SCIB'
s Cash Ratio Range Over the Past 10 Years
Min: 0.48 Med: 4.24 Max: 17.79
Current: 0.48
During the past 12 years, SciBase Holding AB's highest Cash Ratio was 17.79. The lowest was 0.48. And the median was 4.24.
OSTO:SCIB's Cash Ratio is ranked worse than 69.28% of 856
companies
in the Medical Devices & Instruments industry
Industry Median: 1.1
vs OSTO:SCIB: 0.48
SciBase Holding AB Cash Ratio Historical Data
The historical data trend for SciBase Holding AB's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of SciBase Holding AB's Cash Ratio
For the Medical Devices subindustry, SciBase Holding AB's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SciBase Holding AB's Cash Ratio Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, SciBase Holding AB's Cash Ratio distribution charts can be found below:
* The bar in red indicates where SciBase Holding AB's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SciBase Holding AB (OSTO:SCIB) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
SciBase Holding AB Cash Ratio Related Terms
Thank you for viewing the detailed overview of SciBase Holding AB's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
SciBase Holding AB is a medical technology company that develops devices for the evaluation of skin disorders such as skin cancer and atopic dermatitis. SciBase's products include Nevisense and Nevisense Go and to date, the platform addresses the areas of melanoma detection, non-melanoma skin cancer detection, and skin barrier assessment. It is the only FDA-approved device for the detection of melanoma and the only MDR-approved technology for skin cancer detection in Europe. The company operates in two segments which includes skin cancer and skin barrier assessment. Majority of the revenue is generated from skin cancer segment. Its geographical segments are Europe/Rest of the World, the United States/North America, and Asia/Oceania.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
OSTO:SCIB has been successfully added to your 